Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
3.170
-0.260 (-7.58%)
At close: May 9, 2025, 4:00 PM
3.320
+0.150 (4.73%)
After-hours: May 9, 2025, 5:35 PM EDT
Voyager Therapeutics Revenue
Voyager Therapeutics had revenue of $6.47M in the quarter ending March 31, 2025, a decrease of -66.83%. This brings the company's revenue in the last twelve months to $66.96M, down -43.75% year-over-year. In the year 2024, Voyager Therapeutics had annual revenue of $80.00M, down -68.00%.
Revenue (ttm)
$66.96M
Revenue Growth
-43.75%
P/S Ratio
2.97
Revenue / Employee
$389,291
Employees
172
Market Cap
175.42M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 80.00M | -170.01M | -68.00% |
Dec 31, 2023 | 250.01M | 209.10M | 511.16% |
Dec 31, 2022 | 40.91M | 3.49M | 9.33% |
Dec 31, 2021 | 37.42M | -133.71M | -78.14% |
Dec 31, 2020 | 171.13M | 66.74M | 63.93% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Abbott Laboratories | 42.34B |
VYGR News
- 3 days ago - Voyager Reports First Quarter 2025 Financial and Operating Results - GlobeNewsWire
- 11 days ago - Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting - GlobeNewsWire
- 5 weeks ago - Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025 - GlobeNewsWire
- 2 months ago - Voyager Therapeutics, Inc. (VYGR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - GlobeNewsWire
- 2 months ago - Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast - GlobeNewsWire
- 2 months ago - Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer's Disease - GlobeNewsWire
- 2 months ago - The Schall Law Firm Invites Shareholders With Losses In Voyager Therapeutics, Inc. To Join A Securities Fraud Investigation - Accesswire